Lenalidomide

SAN DIEGO — Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind trial presented at ASH Annual Meeting and Exposition.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses how she approaches putting together a treatment plan for a patient with multiple myeloma.

A simultaneous, multidrug, multi-targeted treatment regimen produced remissions in patients with certain types of relapsed or refractory diffuse large B-cell lymphoma in a phase 1b/phase 2 study.

The addition of brentuximab vedotin to lenalidomide and rituximab extended OS among patients with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.

The combination of belantamab mafodotin, pomalidomide and dexamethasone extended PFS compared with standard care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.

Healio spoke with Chakra Chaulagain, MD, about preliminary phase 3 results from the IsKia trial presented at ASH Annual Meeting and Exposition.

Early treatment with lenalidomide resulted in a prolonged time to subsequent therapy in patients with high-risk chronic lymphocytic leukemia, according to extended follow-up data presented at ASH Annual Meeting and Exposition.

Daratumumab combined with bortezomib, lenalidomide and dexamethasone outperformed bortezomib, lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma, according to results of the phase 3 PERSEUS trial.

The combination of mezigdomide and dexamethasone exhibited activity among patients with heavily pretreated multiple myeloma, according to study results published in The New England Journal of Medicine.